Clearmind Medicine (CMND) Non-Current Assets (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Non-Current Assets of $200718.0 for Q2 2026, up 27.26% year-over-year from $157719.0 in Q2 2025, and up 63.51% quarter-over-quarter from $122753.0 in Q1 2026.
Clearmind Medicine (CMND) Non-Current Assets (2021 - 2026) Analysis & Trends
Clearmind Medicine's Non-Current Assets history runs 6 years deep, the most recent figure standing at $200718.0 for Q2 2026.
- In Q2 2026, Non-Current Assets rose 27.26% year-over-year to $200718.0; the TTM figure through Apr 2026 stood at $606258.0 (down 9.99% YoY), while the FY2025 annual figure was $135334.0, down 19.05% from the prior year.
- Non-Current Assets for Q2 2026 stood at $200718.0, up from $122753.0 in the prior quarter.
- The five-year high for Non-Current Assets was $402544.6 in Q4 2022, with the low at $122753.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $158712.0 (2023), against an average of $180637.3.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 112.08% in 2022, then tumbled 60.57% in 2023.
- Clearmind Medicine's Non-Current Assets stood at $402544.6 in 2022, then sank by 60.57% to $158712.0 in 2023, then climbed by 5.33% to $167175.0 in 2024, then decreased by 19.05% to $135334.0 in 2025, then surged by 48.31% to $200718.0 in 2026.
- Business Quant data shows CMND's Non-Current Assets at $200718.0 in Q2 2026, $122753.0 in Q1 2026, and $135334.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Clearmind Medicine | 540,485.35 | -13.05 Mn | - | 200,718.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 200,718.00 |
| Jan 31, 2026 | 122,753.00 |
| Oct 31, 2025 | 135,334.00 |
| Jul 31, 2025 | 147,453.00 |
| Apr 30, 2025 | 157,719.00 |
| Jan 31, 2025 | 170,026.00 |
| Oct 31, 2024 | 167,175.00 |
| Jul 31, 2024 | 178,609.00 |
| Apr 30, 2024 | 154,654.00 |
| Jan 31, 2024 | 254,197.00 |
| Oct 31, 2023 | 158,712.00 |
| Jul 31, 2023 | 132,643.00 |
| Apr 30, 2023 | 154,135.00 |
| Jan 31, 2023 | 172,887.25 |
| Oct 31, 2022 | 402,544.57 |
| Oct 31, 2021 | 189,804.97 |